Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

1.4K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.4K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

409
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
409
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

405
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
405

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sudden Unexpected Postnatal Collapse: A Retrospective Cohort Study Describing Incidence, Risk Factors and Role of Perinatal Transition.

Acta paediatrica (Oslo, Norway : 1992)·2026
Same author

Prospective economic evaluation ancillary to a trial of higher versus lower hemoglobin transfusion thresholds for preterm infants.

Neonatology·2026
Same author

Hypnotic safety suggestions reduce cortisol awakening response and morning heart rate in daily life.

Scientific reports·2026
Same author

Prediction of anxiety in children aged 7-12 during preoperative anaesthesia evaluation - a prospective observational study.

Perioperative medicine (London, England)·2026
Same author

SARS-CoV-2 evolution enhances endocytic uptake while preserving TMPRSS2-dependent fusion.

Frontiers in immunology·2026
Same author

Mechanical ventilation amplifies intratracheal lipopolysaccharide-induced plasma and brainstem inflammation in preterm foetal sheep.

Brain communications·2025

Related Experiment Video

Updated: Apr 29, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

90.5K

Reduction in developmental coordination disorder with neonatal caffeine therapy.

Lex W Doyle1, Barbara Schmidt2, Peter J Anderson3

  • 1Department of Obstetrics and Gynecology, University of Melbourne and The Royal Women's Hospital, Melbourne, Victoria, Australia; Murdoch Childrens Research Institute, Melbourne, Victoria, Australia.

The Journal of Pediatrics
|May 21, 2014
PubMed
Summary

Neonatal caffeine therapy for apnea of prematurity was found to reduce the rate of developmental coordination disorder (DCD) at 5 years of age. This finding offers an additional benefit beyond preventing cerebral palsy.

More Related Videos

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

26.2K
Clinical Practice Protocol of Creative Music Therapy for Preterm Infants and Their Parents in the Neonatal Intensive Care Unit
11:50

Clinical Practice Protocol of Creative Music Therapy for Preterm Infants and Their Parents in the Neonatal Intensive Care Unit

Published on: January 7, 2020

28.6K

Related Experiment Videos

Last Updated: Apr 29, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

90.5K
A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

26.2K
Clinical Practice Protocol of Creative Music Therapy for Preterm Infants and Their Parents in the Neonatal Intensive Care Unit
11:50

Clinical Practice Protocol of Creative Music Therapy for Preterm Infants and Their Parents in the Neonatal Intensive Care Unit

Published on: January 7, 2020

28.6K

Area of Science:

  • Neonatal medicine
  • Developmental pediatrics
  • Neuroscience

Background:

  • Developmental Coordination Disorder (DCD) affects motor skills and is more prevalent than cerebral palsy.
  • Neonatal caffeine therapy is commonly used for apnea of prematurity.

Purpose of the Study:

  • To investigate the impact of neonatal caffeine treatment on the incidence of DCD at five years of age.

Main Methods:

  • Utilized data from the Caffeine for Apnea of Prematurity trial.
  • Assessed 1433 children at 5 years for motor performance (MABC), cerebral palsy, and Full-Scale IQ.
  • Defined DCD as MABC < 5th percentile in children with IQ > 69 and no cerebral palsy diagnosis.

Main Results:

  • The rate of DCD was significantly lower in the caffeine group (11.3%) compared to the placebo group (15.2%).
  • An adjusted odds ratio of 0.71 (95% CI, 0.52-0.97; P=.032) indicated a reduced risk of DCD with caffeine treatment.

Conclusions:

  • Neonatal caffeine therapy for apnea of prematurity is associated with a reduced rate of DCD at 5 years.
  • This suggests an important additional neurodevelopmental benefit of caffeine treatment in preterm infants.